Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis.

Area of Science:

• Neuroscience
• Metabolomics
• Biochemistry

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal motor neuron disease with a median survival of 36 months.
• Pathogenesis of ALS remains inadequately understood, hindering effective treatment development.
• Energy metabolism, including lipid/glucose pathways, TCA cycle, and mitochondrial function, is significantly implicated in ALS.

Purpose of the Study:

• To review metabolic disturbances observed in ALS.
• To discuss therapeutics derived from these metabolic targets.
• To highlight the need for a deeper understanding of metabolic targets in relation to ALS subtypes.

Main Methods:

• Literature review of metabolic perturbations in ALS.
• Analysis of therapeutic strategies targeting metabolic pathways.
• Synthesis of current knowledge on ALS pathogenesis and metabolism.

Main Results:

• Numerous perturbed metabolites in energy metabolism pathways have been identified as potential therapeutic targets.
• Current therapeutic strategies targeting these metabolic pathways have not yielded clinically significant results.
• A gap exists in understanding the relationship between metabolic targets and specific ALS patient profiles.

Conclusions:

• Insufficient knowledge of the link between metabolic targets and patient-specific factors (genetic, environmental) impedes treatment success.
• Improving understanding of pathological mechanisms is essential.
• Future strategies should consider personalized approaches, including dietary interventions and patient stratification based on metabolic status.